TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.
Latest Medications News
The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.
Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Subscribe to MedicineNet's General Health Newsletter